Titan Pharmaceuticals Inc (TTNP)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

400 OYSTER POINT BLVD SAN FRANCISCO, CA 94080

Titan Pharmaceuticals is a biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system disorders. Co. is developing Probuphine for the treatment of opioid dependence. Co. has a continuous drug delivery system, which consists of a small, solid rod made from a mixture of ethylene-vinyl acetate and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the upper arm in an office procedure, and is removed in a similar manner at the end of the treatment period. Co.'s product, Fanapt (Iloperidone) is an atypical antipsychotic, for the treatment of adult patients with schizophrenia.

Data as of 2020-07-04
Market Cap28.641 Million Shares Outstanding95.66 Million Avg 30-day Volume16.642 Million
P/E Ratio Dividend Yield EPS-0.46
Price/Sales8.183 Price cash flow ratio7.9 Price free cash flow ratio-2.3
Book Value0.06 Price to Tangible Book5.35 Alpha-0.05
Short Interest Ratio % Short Interest to Float R-squared0.030947
BETA0.918449 52-week High/Low1.4 / 0.142 Stddev0.222329
View SEC Filings from TTNP instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 27 5 (0.33%)
Aggregate 13F shares on 03/31/2020: 2.84 Million 1.615 Million
Aggregate 13F shares on 12/31/2019: 1.923 Million 525.317 Thousand
Percent change: 47.67% 207.49%
Funds creating new positions: 7 1
Funds Adding to an existing position: 8 2
Funds closing out their position: 6 1
Funds reducing their position: 3
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding TTNP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TTNP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SMITH SCOTT ANDREW

  • Director
0 2020-06-24 0

RUBIN MARC

  • Director
0 2020-03-02 0

HALLBERG DANE SEE REMARKS

  • Officer
0 2019-06-05 0

BHONSLE SUNIL PRESIDENT AND CEO

  • Officer
  • Director
0 2019-04-02 0

BEEBE KATHERINE CHIEF SCIENTIFIC OFFICER

  • Officer
2,387 2019-02-19 0

RECLI FEDERICO SEGHI

  • Director
800,845 2018-10-19 0

AKERS JOSEPH A

  • Director
213,000 2018-09-21 0

MCNAB JAMES R

  • Director
300,000 2018-09-21 0

MACFARLANE M DAVID

  • Director
102,275 2018-09-21 0

KUMAR RAJINDER

  • Director
0 2017-09-15 0

CAVALIER EURELIO M

  • Director
0 2017-02-16 0

BAUER VICTOR J PHD

  • Director
0 2015-12-14 0

SMITH LEY S

  • Director
0 2015-12-14 0

FARRELL ROBERT EDWARD CFO

  • Officer
333,333 2015-04-09 0

HUCKEL HUBERT E MD

  • Director
1,324,170 2014-10-02 0

BRAEBURN PHARMACEUTICALS BVBA SPRL

APPLE TREE CONSOLIDATED BVBA SPRL

APPLE TREE INVESTMENTS S.A.R.L

APPLE TREE PARTNERS IV, L.P.

ATP III GP, LTD.

HARRISON SETH LORING

  • 10% Owner
9,650,000 2013-11-25 0

KAPP JOACHIM FRIEDRICH

  • FORMER DIRECTOR
No longer subject to file 2010-10-13 0

WEIS KONRAD M PHD

  • Director
0 2008-05-30 0

BUCALO LOUIS R MD EXECUTIVE CHAIRMAN

  • Officer
  • Director
0 2008-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments